Core Viewpoint - The article discusses the ongoing conflict between Huaxi Biological and several securities firms regarding the market perception of hyaluronic acid versus collagen protein, highlighting Huaxi's efforts to defend its core business amidst declining performance and market competition [1][10]. Company Performance - Huaxi Biological started with hyaluronic acid and currently holds nearly 50% of the global market share, expanding into downstream medical products, functional skincare, and functional foods [4][5]. - Despite the pandemic, Huaxi maintained positive revenue and profit growth until 2021, with a peak market value exceeding 140 billion yuan [5][7]. - From 2022 to 2024, Huaxi's net profit is projected to decline from 9.71 billion yuan to 1.74 billion yuan, with its market value dropping from over 140 billion yuan to 25.3 billion yuan [7]. Market Comparison - In contrast, collagen protein companies like Juzhi Biological and Jinbo Biological have seen significant growth, with Juzhi's net profit increasing from 1 billion yuan in 2022 to 20.62 billion yuan in 2024, and Jinbo's from 1.09 billion yuan to 7.31 billion yuan, reflecting compound annual growth rates of 43.45% and 158.97%, respectively [8]. - Both companies have achieved new stock price highs, with market values of 87.5 billion HKD and 51.1 billion yuan [8]. Industry Dynamics - The article emphasizes that both hyaluronic acid and collagen are essential components that decrease with age, suggesting that both can positively impact skin health [10][12]. - There is currently no official data to determine which component is superior, but the market's shift towards collagen indicates a growing consumer preference for new ingredients [11][12]. - Huaxi's recent acquisition of a stake in a collagen company and the introduction of collagen products indicate its recognition of the market trend, although its current revenue from collagen remains unspecified [13][14]. Future Outlook - The article suggests that regardless of the outcome of the ongoing dispute, Huaxi may continue to face challenges in growing its hyaluronic acid sales while struggling to establish its collagen product line [14].

Core Viewpoint - The upcoming IPO of Gu Yu, a domestic beauty brand, highlights the changing dynamics in the Chinese beauty industry, shifting from a focus on GMV growth to customer lifetime value as investors become more discerning [1][16]. Industry Overview - The domestic beauty industry has experienced significant fluctuations over the past decade, transitioning from a period of rapid growth to a more rational market environment [1][5]. - The rise of brands like Perfect Diary and Huaxizi was fueled by social media, reaching a peak between 2020 and 2021, but the market soon recognized the unsustainability of the "traffic equals brand" model, leading to a decline starting in 2022 [2][5]. Financial Performance - In 2022, the beauty and personal care industry saw a dramatic drop in financing, with 74 investment events totaling approximately 7.949 billion yuan, a year-on-year decrease of 72.88% [5]. - Recent financial reports indicate that companies like Beitaini and Huaxi Biological have faced declining revenues and profits, with Beitaini's net profit dropping by 33.53% year-on-year [5][6]. Gu Yu's Growth Strategy - Gu Yu has achieved explosive growth in GMV, surpassing 5 billion yuan in 2024, with a year-on-year growth rate exceeding 40% [10]. - The brand has effectively utilized major social media platforms for marketing, starting with Taobao Live in 2016 and expanding to platforms like Xiaohongshu, Kuaishou, and Douyin [7][9]. Challenges and Risks - Gu Yu's reliance on a marketing-driven growth strategy mirrors that of earlier successful brands, raising concerns about profitability as marketing costs rise and consumer loyalty wanes [11][12]. - The brand faces significant challenges in product differentiation and market competition, particularly in the essence category where it primarily generates revenue [11][12]. Market Dynamics - The beauty industry is witnessing a shift in focus from traffic-driven growth to sustainable business models, emphasizing profitability and customer retention [16][18]. - The competitive landscape is intensifying, with new customer acquisition costs rising and customer lifetime value decreasing, leading to lower repurchase rates [18][20]. Regulatory Environment - Stricter regulations in the beauty industry, particularly regarding marketing claims, are expected to impact smaller brands that rely heavily on concept marketing [22]. - The evolving consumer preferences among younger generations indicate a shift towards valuing product efficacy over brand popularity, challenging traditional marketing strategies [22]. Conclusion - Gu Yu's IPO represents a critical moment for the domestic beauty industry, as it must navigate the transition from a focus on rapid growth to establishing a sustainable business model that can withstand market pressures and changing consumer expectations [23].

Core Viewpoint - Huaxi Biological criticized ten research reports from nine brokerages, claiming they misled the market by promoting a "hyaluronic acid obsolescence theory" in favor of recombinant collagen products [2][3][5] Group 1: Research Reports Criticism - Huaxi Biological specifically named four reports from brokerages including Huatai Securities and Anxin Securities, which emphasized the advantages of recombinant collagen over hyaluronic acid in terms of efficacy and safety [3][5] - The reports in question did not explicitly use the term "obsolete" but suggested that collagen had superior applications in certain scenarios [5] - Huaxi Biological's article indicated that the emergence of the "hyaluronic acid obsolescence" narrative was driven by "restless capital" seeking new investment themes [3][9] Group 2: Timeline and Context - The criticism of the research reports is rooted in a timeline starting from 2022, when the recombinant collagen concept gained traction in the capital market [7][10] - Huaxi Biological itself entered the recombinant collagen market in April 2022 by acquiring a 51% stake in Beijing Yierkang Biological Engineering for 233 million yuan [9] - The reports were published between 2022 and 2024, with the earliest being from August 2022 and the latest from February 2024 [8] Group 3: Regulatory and Compliance Issues - The article raised questions about the compliance and independence of the research reports, referencing the "Interim Regulations on the Release of Securities Research Reports" which mandates objectivity and fairness [10][11] - There were indications that some brokerages had deleted the criticized reports from the WIND platform, although they remained accessible on other platforms like Choice [5][11] - The production process of research reports involves ensuring data legality and undergoing compliance checks before publication, highlighting the importance of rigorous standards in the industry [11]

沪指5月22日下跌0.22%，申万所属行业中，今日上涨的有3个，涨幅居前的行业为银行、传媒、家用电 器，涨幅分别为1.00%、0.12%、0.04%。跌幅居前的行业为美容护理、社会服务，跌幅分别为2.03%、 1.80%。美容护理行业位居今日跌幅榜首位。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 002094 | 青岛金王 | 6.60 | 38.89 | 49250.10 | | 600249 | 两面针 | 4.83 | 22.21 | 16705.65 | | 001328 | 登康口腔 | 2.73 | 14.01 | 2803.29 | | 688363 | 华熙生物 | -1.01 | 1.08 | 1449.76 | | 002511 | 中顺洁柔 | -0.14 | 1.34 | 1289.38 | | 300886 | 华业香料 | -5.41 | 21.25 | 262.17 | | 300955 | 嘉亨家化 | 3.58 | 24.50 | 122.21 | | 30 ...

Market Performance - The micro-cap stock index opened lower but surged over 1% to reach a historical high before closing down 1.37% [2] - The North Exchange 50 index experienced a significant decline, closing down 6.15% after reaching a historical high the previous day [2] Reasons for Adjustment - Analysts suggest that the recent market adjustment is due to both internal and external factors, including a historical pattern where high levels of congestion in the market led to significant pullbacks [3] - The micro-cap sector may face profit-taking pressure as funds become overly concentrated, potentially shifting market preference towards mid and large-cap stocks [3] Company-Specific Insights - Jinbo Biological (832982.BJ) saw its stock price drop over 17% during the day, closing down 14.55%. The company attributed the decline to market factors rather than specific company issues [3] - Jinbo Biological's stock had been on a steady rise since March, reaching a peak of 589.98 CNY per share on May 22, with a total market capitalization exceeding 52 billion CNY [3] - The company is recognized for its innovative medical device, the "recombinant type III humanized collagen freeze-dried fiber," which is the first of its kind in China, laying a solid foundation for clinical applications and industrial transformation [4] Market Sentiment - The poor results from the U.S. 20-year Treasury auction have led to a negative sentiment in the U.S. financial markets, potentially increasing global risk aversion and cautiousness [5] - There are indications that micro-cap stock investments may be overly crowded, with trading volumes surpassing previous highs, signaling significant overbought conditions [5]

Core Viewpoint - The ongoing debate between hyaluronic acid and recombinant collagen in the capital market highlights the challenges faced by companies like Huaxi Biological, which is experiencing a decline in revenue and net profit after reaching a peak in 2022 [2][6]. Group 1: Company Response and Market Dynamics - Huaxi Biological criticized the recent reports from several securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports misrepresent the safety and efficacy of hyaluronic acid [3][4]. - The company emphasized the importance of a healthy industry ecosystem, stating that without it, no company can achieve long-term success or maintain competitive advantages [5][6]. - Huaxi Biological is undergoing a comprehensive management transformation in 2024, including business process restructuring and digitalization, to address the challenges in the current operating environment [2][6]. Group 2: Financial Performance - In 2024, Huaxi Biological reported a revenue of 5.371 billion yuan, a year-on-year decrease of 11.61%, and a net profit of 174 million yuan, down 70.59% [6]. - The skin science innovation business, which accounts for nearly half of the company's revenue, saw a significant decline of 31.62% in revenue, totaling 2.569 billion yuan [6]. - In contrast, the medical terminal business achieved a revenue of 1.44 billion yuan in 2024, marking a growth of 32.03% [7]. Group 3: Industry Trends and Competition - The medical aesthetics industry is witnessing a shift from hyaluronic acid to recombinant collagen and other regenerative products, driven by evolving consumer preferences and technological advancements [5][9]. - The market for recombinant collagen is growing rapidly, with companies like Jinbo Biological and Giant Bio achieving substantial revenue increases in 2024, indicating a competitive landscape with low market concentration [8][9]. - Huaxi Biological is also investing in recombinant collagen research and development, aiming to leverage synthetic biology for technological upgrades and high-quality applications [7][8].

5月21日晚间，华熙生物官方公众号发布消息，再次就透明质酸、重组胶原蛋白等问题进行回应。 在谈到对透明质酸市场的现在和未来看法时，华熙生物表示，任何产业领域都有一个共同点：当某一领域展现出良好 的赚钱效应后就会吸引大量资本和企业涌入，随之引发价格和利润的下滑。这个现象在透明质酸领域发生过，在其他 任何领域都会发生。 但并非所有的企业都会在低端竞争，华熙生物的进阶道路并非特殊，是在中国很多企业中发生过的，这就是进入高端 透明质酸市场，做精做深，做出新的延伸和高度。在医用和试验用的高端透明质酸和生物制造领域，华熙生物依靠健 全的酶库和全球最大的中式转化平台，占据着高端市场技术与品牌的制高点，并依靠透明质酸打开了庞大的糖生物产 业和细胞生物学的认知窗口。 对于如何看待重组胶原蛋白，华熙生物方面指出，首先，就像不能比较肝脏与肾脏孰强孰弱一样，在很多场景下，也 无法比较透明质酸（HA）与胶原蛋白孰强孰弱。透明质酸和胶原蛋白都是人体重要的物质，透明质酸与胶原蛋白的 互动，构成了细胞外基质ECM功能的核心，这两个物质形成了信号共生、力学共生、病理共损的三重关系： 1、在力学层面，HA凭借其卓越的高保水性和粘弹性，在细胞外基 ...

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several securities firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [2][11]. Summary by Sections Company Background - Huaxi Biological, once a darling of the capital market, saw its stock peak at 313.1 yuan and market capitalization exceed 150 billion yuan, but has since experienced a significant decline, with its stock price dropping to 52.61 yuan and market cap to 25.3 billion yuan as of May 21 [3][12]. Market Dynamics - The rise of recombinant collagen protein companies like Juzhi Biological and Jinbo Biological has shifted capital focus, with these companies achieving record highs in stock prices [4][14]. - Huaxi Biological's performance has been declining, particularly in its functional skincare segment, while the recombinant collagen protein sector is experiencing rapid growth [4][20]. Securities Firms' Reports - Huaxi Biological criticized reports from nine securities firms that favor recombinant collagen over hyaluronic acid, claiming these reports mislead the market [6][9]. - Specific reports from Huatai Securities, Guojin Securities, and others highlighted the advantages of recombinant collagen, such as its biological features and safety, which Huaxi disputes [7][8]. Industry Trends - The market for recombinant collagen products in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [12]. - Huaxi Biological's sales of hyaluronic acid accounted for 44% of the global market in 2021, but its revenue has been declining due to challenges in its functional skincare business [12][17]. Financial Performance - Huaxi Biological's revenue and net profit have been declining, with 2023 revenue at 6.08 billion yuan and a net profit of 593 million yuan, reflecting a year-on-year decrease of 4.45% and 38.97%, respectively [17][18]. - The company's functional skincare revenue peaked in 2022 but has since dropped, leading to overall performance issues [17][19]. Strategic Response - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a shift in branding and operational strategies [19][20]. - The company has also made acquisitions to enter the collagen market, although its recent acquisition has not yet proven profitable [20]. Competitive Landscape - The article notes that both hyaluronic acid and recombinant collagen have their respective advantages, with hyaluronic acid still holding a competitive edge in certain applications despite market challenges [21].

【要闻报道】 美债要崩？20年期美债拍卖遇冷 需防范抛售潮对全球市场的冲击风险 自穆迪下调美国主权信用评级以来，美债市场走势牵动人心。北京时间5月22日凌晨，20年期美债标售 以相对惨淡的结果落下帷幕。本次拍卖的最终得标利率为5.047%，这是20年期美债拍卖的收益率第二 次突破5%大关。得标利率较预发行利率5.035%高出约1.2个基点，创下去年12月以来的最大尾部利差。 疲软的投标倍数也引发关注，本次拍卖的投标倍数为2.46，是自2月以来的最低水平。 点评：分析认为，本次拍卖虽称不上"灾难性"，但其糟糕程度足以推高美债收益率。叠加减税法案扰 动，20年期美债收益率日内最高升至5.127%，30年期美债收益率也重新突破5%大关。 实施"六大行动"！上海发布提振消费专项行动方案 为贯彻落实党中央、国务院关于大力提振消费的决策部署，深化国际消费中心城市建设，切实发挥消费 对经济发展的基础性作用，近日，市政府办公厅印发《上海市提振消费专项行动方案》。《行动方案》 提出"城乡居民增收、消费能力保障支持、服务消费提质升级、大宗消费更新、新型消费培育、消费环 境提升"等六大行动和第七部分的"完善支持政策"。 点评：在新 ...

Core Viewpoint - The article discusses the conflict between Huaxi Biological and several brokerage firms regarding the comparison of hyaluronic acid and recombinant collagen protein, with Huaxi asserting that the notion of hyaluronic acid being outdated is a misleading narrative driven by "restless capital" [1][9]. Group 1: Company Performance - Huaxi Biological's stock price peaked at 313.1 yuan with a market value exceeding 150 billion yuan, but as of May 21, it has plummeted to 52.61 yuan, with a market value of only 25.3 billion yuan, representing a loss of over 120 billion yuan in market capitalization [2][10]. - The company's revenue for 2023 and 2024 was 6.076 billion yuan and 5.371 billion yuan, respectively, showing a year-on-year decline of 4.45% and 11.61% [14]. - The net profit attributable to shareholders for the same years was 593 million yuan and 174 million yuan, reflecting a significant decline of 38.97% and 70.59% [14]. Group 2: Market Dynamics - The market is witnessing a shift in focus from hyaluronic acid to recombinant collagen protein, with companies like Juzhi Biological and Jinbo Biological experiencing significant stock price increases and strong revenue growth [12][17]. - The recombinant collagen protein market in China is projected to grow at a compound annual growth rate of 44.93%, reaching 58.57 billion yuan by 2025 [9]. Group 3: Industry Comparison - Huaxi Biological argues that the claims made by brokerage reports regarding the superiority of recombinant collagen protein over hyaluronic acid are misleading and lack scientific backing [5][18]. - Both hyaluronic acid and recombinant collagen protein have their respective advantages in different applications, with hyaluronic acid still holding competitive strength due to its established market presence [18]. Group 4: Company Strategy - In response to declining performance, Huaxi Biological is restructuring its management and focusing on core competencies, including a renewed emphasis on its strengths in hyaluronic acid [16]. - The company has also made strategic acquisitions, such as a 51% stake in Beijing Yierkang Biological Engineering, to enter the animal-derived collagen protein market, although this subsidiary reported losses in 2024 [17].